Aberdeen Group
ALXN

Aberdeen Group’s Alexion Pharmaceuticals ALXN Stock Holding History

Aberdeen Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-84,822
Closed -$15.6M – 1075
2021
Q2 		$15.6M Sell
84,822
-5,150
-6% -$884K 0.03% 401
2021
Q1 		$13.8M Sell
89,972
-1,907
-2% -$295K 0.03% 427
2020
Q4 		$14.4M Sell
91,879
-2,488
-3% -$320K 0.04% 379
2020
Q3 		$10.8M Sell
94,367
-16,539
-15% -$1.78M 0.03% 407
2020
Q2 		$12.4M Sell
110,906
-19,180
-15% -$2.04M 0.03% 368
2020
Q1 		$11.7M Buy
130,086
+13,632
+12% +$1.34M 0.04% 367
2019
Q4 		$12.6M Buy
116,454
+5,486
+5% +$587K 0.03% 415
2019
Q3 		$10.9M Buy
110,968
+11,311
+11% +$1.27M 0.03% 430
2019
Q2 		$13.1M Buy
99,657
+1,664
+2% +$214K 0.03% 445
2019
Q1 		$13.2M Buy
97,993
+30,026
+44% +$3.73M 0.03% 441
2018
Q4 		$6.67M Sell
67,967
-1,905
-3% -$225K 0.02% 522
2018
Q3 		$9.71M Buy
69,872
+6,873
+11% +$862K 0.02% 492
2018
Q2 		$7.82M Buy
62,999
+12,557
+25% +$1.47M 0.02% 520
2018
Q1 		$5.62M Buy
50,442
+1,401
+3% +$167K 0.01% 531
2017
Q4 		$5.87M Buy
49,041
+526
+1% +$64.1K 0.01% 531
2017
Q3 		$6.81M Buy
+48,515
New +$6.59M 0.01% 515

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Aberdeen Group's ALXN Position: Q3 2021 in Review

Aberdeen Group sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 84,822 shares — an estimated $15.6M sold.

Aberdeen Group first reported a position in ALXN in Q3 2017 and held it in 16 quarters. The position peaked at $15.6M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Aberdeen Group reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Aberdeen Group sold 84,822 Alexion Pharmaceuticals shares in Q3 2021, an estimated $15.6M.
  • Aberdeen Group first reported a position in Alexion Pharmaceuticals in Q3 2017 and held it in 16 quarters.
  • Aberdeen Group's Alexion Pharmaceuticals position peaked at $15.6M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Aberdeen Group's 13F filing for Q3 2021, filed 15 Nov 2021.